GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Growth hormone secretagogues. Clinical experience and therapeutic potential.
Laron. Z Z
Key Findings
- GHRP‑6 and related hexa‑/heptapeptides are potent secretagogues that increase GH and IGF‑1 levels.
- Their effect is synergistic with GHRH but requires the presence of GHRH receptors (GHRH‑dependent).
- They are effective via intravenous, oral, or subcutaneous administration and produce GH‑like metabolic effects, including accelerated growth in children.
- Short‑ and long‑term use in adults and children has shown minimal adverse effects, aside from a partial down‑regulation phenomenon.
Practical Outcomes
- For biohackers, GHRP‑6 can be used to raise GH/IGF‑1 for potential benefits in muscle growth, fat loss, recovery, and overall metabolic health. It can be taken subcutaneously or orally, but pairing it with a GHRH analog may boost its effectiveness. Users should watch for signs of hormonal down‑regulation and cycle the peptide accordingly.
Summary
The abstract says that GHRP‑6 and similar short peptides can strongly stimulate the body’s own growth hormone (GH) and IGF‑1, especially when used together with a GH‑releasing hormone (GHRH). They work whether you inject them, take them by mouth, or give them under the skin, and they have been shown to cause the same metabolic changes as GH, like faster growth in kids, with few reported side effects.
Abstract
In recent years, several biosynthetic hexa- and heptapeptides, as well as nonpeptide bezolactam derivatives, have been found to be potent growth hormone (GH) secretagogues. They act synergistically with GH-releasing hormone (GHRH) but via different receptors, and are GHRH dependent. All are active when administered intravenously, orally or subcutaneously. Short and long term experience in adults and children has proven that these drugs evoke the metabolic changes induced by GH and insulin-like growth factor-1 (IGF-1), including acceleration of growth velocity in children. With the exception of a partial downregulation phenomenon, no adverse effects have been reported so far. This new class hormone-like drugs acting GH secretagogues may have immense clinical potential.
Study Information
pubmed
1995
1995-10-01T00:00:00.000Z
10.2165/00003495-199550040-00002
4
48